Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M
June 16, 2022 | Startland News Staff
Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.
Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.
Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.
Click here to read more about Artio’s $12 million funding infusion in 2021.
“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.
“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.”
Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.
Click here to learn more about Artio’s portfolio of products.
2022 Startups to Watch
stats here
Related Posts on Startland News
Here’s how Bungii delivered spot No. 981 in its Inc. 5000 fastest-growing companies debut
Nailing Bungii’s geographic expansion model has unlocked significant growth, said Ben Jackson, detailing a years-long evolution that earned his Kansas City-built final-mile delivery carrier a coveted spot on the latest Inc. 5000 fastest-growing companies list. “Bungii’s network is becoming one of the largest sharing economy footprints across the U.S.,” explained Jackson, who co-founded the company…
Caterpillar subsidiary expands into KC, turning dirt to create 85 jobs in revitalized industrial corridor near riverfront
A multi-million dollar expansion project is expected to put an aging manufacturing site back on track in Kansas City, officials at Progress Rail announced Monday, noting the converted operation will focus on re-manufacturing railcar wheelsets and bearings. Progress Rail — a wholly owned subsidiary of Caterpillar Inc. — expects to bring 85 new full-time jobs…
Emerging KC space tech startup relocating to Colorado to build autonomous factory
A space tech startup that shot into orbit from its West Bottoms headquarters in Kansas City has announced plans to build its first smart factory in Colorado — relocating operations to Broomfield to join the Centennial State’s “robust aerospace and defense ecosystem.” “Colorado is home to some of the best aerospace, defense, and manufacturing talent…
H&R Block CEO files retirement plans; company sets ‘smooth transition’ to new chief executive
Announcing his plan to retire at the end of 2025, the CEO for one of Kansas City’s most iconic businesses called his work at H&R Block the past eight years “the honor of a lifetime.” “We have elevated Block’s relevance, built an extraordinary culture, made bold bets to drive growth, rebuilt about every piece of…